<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006736.pub2" GROUP_ID="HIV" ID="791606071109145732" MERGED_FROM="" MODIFIED="2014-06-18 12:41:10 -0700" MODIFIED_BY="Hacsi Horvath" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2014-06-18 12:41:10 -0700" NOTES_MODIFIED_BY="Hacsi Horvath" REVIEW_NO="001" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2014-06-18 12:41:10 -0700" MODIFIED_BY="Hacsi Horvath">
<TITLE>Iron supplementation for reducing morbidity and mortality in children with HIV</TITLE>
<CONTACT>
<PERSON ID="C68C71C282E26AA20078D4E67EFD5A4D" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Ifedayo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Adetifa</LAST_NAME>
<SUFFIX/>
<POSITION>Research Clinician/Paediatrician</POSITION>
<EMAIL_1>iadetifa@mrc.gm</EMAIL_1>
<EMAIL_2>ifedayoadetifa@yahoo.co.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Bacterial Diseases Programme</DEPARTMENT>
<ORGANISATION>Medical Research Council (UK) Laboratories</ORGANISATION>
<ADDRESS_1>Atlantic Boulevard, Fajara</ADDRESS_1>
<ADDRESS_2>PO Box 273</ADDRESS_2>
<CITY>Banjul</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GM">Gambia</COUNTRY>
<PHONE_1>+220 449 5442 ext. 441/359</PHONE_1>
<PHONE_2/>
<FAX_1>+220 449 6513</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-06-18 12:35:34 -0700" MODIFIED_BY="Hacsi Horvath">
<PERSON ID="C68C71C282E26AA20078D4E67EFD5A4D" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Ifedayo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Adetifa</LAST_NAME>
<SUFFIX/>
<POSITION>Research Clinician/Paediatrician</POSITION>
<EMAIL_1>iadetifa@mrc.gm</EMAIL_1>
<EMAIL_2>ifedayoadetifa@yahoo.co.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Bacterial Diseases Programme</DEPARTMENT>
<ORGANISATION>Medical Research Council (UK) Laboratories</ORGANISATION>
<ADDRESS_1>Atlantic Boulevard, Fajara</ADDRESS_1>
<ADDRESS_2>PO Box 273</ADDRESS_2>
<CITY>Banjul</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GM">Gambia</COUNTRY>
<PHONE_1>+220 449 5442 ext. 441/359</PHONE_1>
<PHONE_2/>
<FAX_1>+220 449 6513</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16818" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Uduak</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Okomo</LAST_NAME>
<SUFFIX/>
<POSITION>Paediatrician/Research Clinician</POSITION>
<EMAIL_1>uokomo@mrc.gm</EMAIL_1>
<EMAIL_2>uokomo@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Viral Diseases Programme</DEPARTMENT>
<ORGANISATION>Medical Research Council (UK)</ORGANISATION>
<ADDRESS_1>Atlantic Boulevard</ADDRESS_1>
<ADDRESS_2/>
<CITY>Fajara</CITY>
<ZIP>P.O. Box 273</ZIP>
<REGION/>
<COUNTRY CODE="GM">Gambia</COUNTRY>
<PHONE_1>+220 4497114 ext: 321</PHONE_1>
<PHONE_2>+220 7736011</PHONE_2>
<FAX_1>+220 4495919</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2014-06-18 12:41:10 -0700" MODIFIED_BY="Tara Horvath" NOTES="&lt;p&gt;Minor update: 22/07/08&lt;/p&gt;" NOTES_MODIFIED="2014-06-18 12:41:10 -0700" NOTES_MODIFIED_BY="Tara Horvath">
<UP_TO_DATE>
<DATE DAY="29" MONTH="9" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="29" MONTH="9" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="18" MONTH="6" YEAR="2024"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2014-06-18 12:39:10 -0700" MODIFIED_BY="Tara Horvath">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2014-06-18 12:39:10 -0700" MODIFIED_BY="Tara Horvath">
<DATE DAY="18" MONTH="6" YEAR="2014"/>
<DESCRIPTION>
<P>This review will not be updated. It should be considered out of date. It has been superseded by this review:</P>
<P>Irlam JH, Siegfried N, Visser ME, Rollins NC. Micronutrient supplementation for children with HIV infection. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD010666. DOI: 10.1002/14651858.CD010666. <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010666/full">Link to Cochrane Library</A>. [<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/24114375">PubMed</A>]</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-06-18 12:36:31 -0700" MODIFIED_BY="Tara Horvath">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-06-18 12:36:31 -0700" MODIFIED_BY="Tara Horvath">
<DATE DAY="17" MONTH="2" YEAR="2009"/>
<DESCRIPTION>
<P>Correct affiliation.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-02-17 14:24:52 -0800" MODIFIED_BY="Tara Horvath">
<DATE DAY="29" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>MRC Laboratories, Fajara, P.O. Box 273, Banjul</NAME>
<COUNTRY CODE="GM">Gambia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>European and Developing Countries Clinical Trials Partnership</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>South African Cochrane Centre HIV/AIDS Mentoring Programme</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-06-18 12:40:11 -0700" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-06-18 12:40:04 -0700" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-28 13:12:03 -0700" MODIFIED_BY="Tara Horvath">Giving iron supplements to improve outcomes in children with HIV/AIDS</TITLE>
<SUMMARY_BODY MODIFIED="2014-06-18 12:40:04 -0700" MODIFIED_BY="[Empty name]">
<P>
<B>This review will not be updated. It should be considered out of date. It has been replaced by this review:</B>
</P>
<P>
<B>Irlam JH, Siegfried N, Visser ME, Rollins NC. Micronutrient supplementation for children with HIV infection. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD010666. DOI: 10.1002/14651858.CD010666.</B> <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010666/full">Link to Cochrane Library</A>. [<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/24114375">PubMed</A>]</P>
<P>
<BR/>Anaemia is one of the most common haematologic problem found in children with HIV/AIDS, second only to depletion of CD4/helper T lymphocytes. Anaemia in HIV-infected children can be caused by direct effects of HIV, other prevalent infections and opportunistic infections on blood producing cells; micronutrient deficiencies; or side effects of drugs used to prevent or treat opportunistic infections and HIV. Deficiency of iron, a micronutrient, is by far the most common cause of nutritional anaemia worldwide. Given the global prevalence of iron deficiency anaemia, especially in parts of the world where childhood HIV infections are quite prevalent, it is likely many HIV-infected children also are iron deficient. There is very little known, however, about the contribution of iron deficiency to anaemia observed in children with HIV/AIDS. Iron supplementation currently is given routinely to anaemic children in most of the developing countries where there also are high rates of HIV infection, and no obvious adverse effects have been observed. However, there are reports of a deleterious effect of iron supplementation during ongoing infections, including malaria. As iron deficiency and iron deficiency anaemia are common in HIV-infected children in high-prevalence areas with concerns about possible deleterious effects of iron, we looked for randomised clinical trials that demonstrated benefits or disadvantages of iron supplements, regardless of type or preparation. We did not find any such trials and conclude that there is a need for large multi-centre trials to examine these questions.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-06-18 12:39:37 -0700" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-06-18 12:39:37 -0700" MODIFIED_BY="[Empty name]">
<P>
<B>This review will not be updated. It should be considered out of date. It has been superseded by this review:</B>
</P>
<P>
<B>Irlam JH, Siegfried N, Visser ME, Rollins NC. Micronutrient supplementation for children with HIV infection. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD010666. DOI: 10.1002/14651858.CD010666.</B> <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010666/full">Link to Cochrane Library</A>. [<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/24114375">PubMed</A>]</P>
<P>The most prevalent haematologic disturbance associated with HIV in children (apart from CD4 lymphocytopenia) is anaemia. Anaemia associated with HIV arises from multiple mechanisms, including the direct inhibitory effect of HIV on red cell precursors, other locally prevalent and/or opportunistic infections, micronutrient deficiency, anaemia of chronic disease, and as a consequence of medicines given for HIV and/or other concurrent illnesses. Iron deficiency is the most common cause of nutritional anaemia globally. There is significant geographical overlap of areas of the world where iron deficiency anaemia (IDA) and paediatric HIV are distributed. Given the high prevalence of IDA, it is likely that many HIV-infected children also are iron deficient. The contribution of iron deficiency to anaemia in HIV-infected children has been described but is incompletely understood. Currently, iron supplementation for anaemic infants and children is routinely practiced without any obvious effect in most developing countries, which bear most of the burden of global paediatric HIV infections.</P>
<P>Because iron deficiency and IDA are common in HIV-infected children in high-prevalence areas and because there are concerns about possible deleterious effects of iron, this review aims to assess the evidence for iron supplementation for reducing morbidity and mortality in HIV-infected children.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-11-11 11:07:04 -0800" MODIFIED_BY="[Empty name]">
<P>To determine whether iron supplementation improves clinical, immunologic, and virologic outcomes in children infected with HIV</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-11-11 11:08:05 -0800" MODIFIED_BY="[Empty name]">
<P>We used the comprehensive search strategy developed specifically by the Cochrane HIV/AIDS Review Group to identify HIV/AIDS randomised controlled trials, and searched the following electronic databases: MEDLINE (searched November 2007); Embase (searched December 2007); and CENTRAL (December 2007). This search was supplemented with a search of AIDSearch (searched December 2007) and NLM Gateway (searched December 2007) to identify relevant conference abstracts, as well as a search of the reference lists of all eligible articles. The search was not limited by language or publication status.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-11-11 11:10:08 -0800" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) of iron supplementation in any form and dose in HIV-infected children aged 12 years and younger.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>We independently screened the results of the search to select potentially relevant studies and to retrieve the full articles. We independently applied the inclusion criteria to the potentially relevant studies. <BR/>No studies were identified that fulfilled the selection criteria.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>No RCTs of iron supplementation in HIV-infected children were found.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-11-11 12:22:38 -0800" MODIFIED_BY="[Empty name]">
<P>
<B>Implications for clinical practice</B>:</P>
<P>The current clinical practice of iron supplementation in HIV-infected children is based on weak evidence comprising observational studies and expert opinions.</P>
<P>
<B>Implications for research:</B>
</P>
<P>High-quality RCTs of iron supplementation are urgently required, especially in areas with significant overlap of high prevalence of HIV, iron deficiency anaemia, and malaria. Policy makers should prioritise funding for these trials.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-06-18 12:40:11 -0700" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-06-18 12:40:11 -0700" MODIFIED_BY="[Empty name]">
<P>
<B>This review will not be updated. It should be considered out of date. It has been superseded by this review:</B>
</P>
<P>
<B>Irlam JH, Siegfried N, Visser ME, Rollins NC. Micronutrient supplementation for children with HIV infection. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD010666. DOI: 10.1002/14651858.CD010666.</B> <A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010666/full">Link to Cochrane Library</A>. [<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/24114375">PubMed</A>]</P>
<P>Haematologic abnormalities are common in children with HIV. The most prevalent haematologic disturbance associated with HIV in children (apart from CD4 lymphocytopenia) is anaemia (<LINK REF="REF-Ellaurie-1990" TYPE="REFERENCE">Ellaurie 1990</LINK>; <LINK REF="REF-Forsyth-1996" TYPE="REFERENCE">Forsyth 1996</LINK>; <LINK REF="REF-Eley--2002" TYPE="REFERENCE">Eley 2002</LINK>; <LINK REF="REF-Adetifa-2006" TYPE="REFERENCE">Adetifa 2006</LINK>). It is a associated with more-rapid progression to AIDS and decreased survival rates (<LINK REF="REF-Forsyth-1996" TYPE="REFERENCE">Forsyth 1996</LINK>; <LINK REF="REF-Moore-1999" TYPE="REFERENCE">Moore 1999</LINK>). The prevalence of anaemia in paediatric HIV ranges from 23% to 48% in high income countries (<LINK REF="REF-Pizzo-1988" TYPE="REFERENCE">Pizzo 1988</LINK>; <LINK REF="REF-Butler-1991" TYPE="REFERENCE">Butler 1991</LINK>; <LINK REF="REF-Forsyth-1996" TYPE="REFERENCE">Forsyth 1996</LINK>) to 78% to 90% in low income countries (<LINK REF="REF-Adewuyi-1994" TYPE="REFERENCE">Adewuyi 1994</LINK>; <LINK REF="REF-Totin--2002" TYPE="REFERENCE">Totin 2002</LINK>; <LINK REF="REF-Clark--2002" TYPE="REFERENCE">Clark 2002</LINK>; <LINK REF="REF-Adetifa-2006" TYPE="REFERENCE">Adetifa 2006</LINK>). Anaemia associated with HIV can arise from multiple mechanisms, including direct infection of haematopoietic precursor cells (<LINK REF="REF-Zauli-1994" TYPE="REFERENCE">Zauli 1994</LINK>; <LINK REF="REF-Carr-1998" TYPE="REFERENCE">Carr 1998</LINK>), malaria, opportunistic infections, micronutrient deficiency, anaemia of chronic disease (ACD), and direct effects of medications, such as the antiretroviral zidovudine, as well as other drugs given for prophylaxis and treatment of opportunistic infections (<LINK REF="REF-Richman-1987" TYPE="REFERENCE">Richman 1987</LINK>; <LINK REF="REF-Pizzo-1988" TYPE="REFERENCE">Pizzo 1988</LINK>; <LINK REF="REF-Semba-2001" TYPE="REFERENCE">Semba 2001</LINK>; <LINK REF="REF-Totin--2002" TYPE="REFERENCE">Totin 2002</LINK>). Anaemia of chronic disease is the most common type of anaemia and is due to the inhibitory effect of inflammatory cytokines released during chronic diseases on erythropoiesis. These cytokines also blunt the response to erythropoietin, prevent the release of iron from the reticuloendothelial stores, and shorten red cell survival time (<LINK REF="REF-Coyle-1997" TYPE="REFERENCE">Coyle 1997</LINK>; <LINK REF="REF-Allen-1998" TYPE="REFERENCE">Allen 1998</LINK>).</P>
<P>Iron deficiency is the most common cause of anaemia of micronutrient-related aetiology worldwide, affecting about 50% of women and children in developing countries and about 25% of men (<LINK REF="REF-WHO-2001" TYPE="REFERENCE">WHO 2001</LINK>). There is considerable geographic overlap of areas of the world where both iron deficiency anaemia (IDA) and paediatric HIV are distributed. These areas include sub-Saharan Africa and Southeast Asia, where iron supplementation is routinely given to anaemic children and pregnant women. Given this high prevalence of IDA, it is likely that many HIV-infected children also are iron deficient. The contribution of iron deficiency to the anaemia of HIV in children has been described but is not completely understood. Iron deficiency, iron depletion, and iron-deficient erythropoiesis have been found in over 50% of anaemic HIV-infected children. This finding is positively correlated with the severity of clinical disease and immunologic suppression (<LINK REF="REF-Eley--2002" TYPE="REFERENCE">Eley 2002</LINK>; <LINK REF="REF-Totin--2002" TYPE="REFERENCE">Totin 2002</LINK>). Iron status usually is determined by measuring haemoglobin concentration and red cell indices; microscopically examining red cell morphology, plasma ferritin, transferrin, and total iron binding capacity (TIBC); and directly determining levels of iron. Distinguishing ACD from IDA as the underlying cause of anaemia in HIV can be difficult because many of the direct and surrogate markers of iron status behave like acute phase reactants and may be elevated in chronic inflammatory diseases, even in the presence of iron deficiency (<LINK REF="REF-Feelders--1999" TYPE="REFERENCE">Feelders 1999</LINK>). Elevated levels of ferritin and transferrin have been found in iron-deficient HIV-infected children with profound immunosuppression and viral burden and advanced clinical stage of illness (<LINK REF="REF-Eley--2002" TYPE="REFERENCE">Eley 2002</LINK>; <LINK REF="REF-Totin--2002" TYPE="REFERENCE">Totin 2002</LINK>). It is therefore logical to contemplate supplemental or therapeutic courses of iron in HIV-infected children. At present there are no guidelines for the prevention and management of anaemia in HIV-infected persons, including children (<LINK REF="REF-Volberding--2000" TYPE="REFERENCE">Volberding 2000</LINK>).</P>
<P>There are reasonable hypothetical considerations and in vitro experiments that suggest that excessive iron may have deleterious effects in persons living with HIV. These effects include accelerated progress to AIDS with increased viral load and falling CD4 counts, impaired innate and specific immune responses, increased oxidative stress, and reduced survival rates (<LINK REF="REF-Boelaert--1996" TYPE="REFERENCE">Boelaert 1996</LINK>; <LINK REF="REF-Savarino-1999" TYPE="REFERENCE">Savarino 1999</LINK>). This evidence is based largely on several observational studies in HIV-infected adults from populations with little or no prevalent iron deficiency (<LINK REF="REF-Costagliola-1994" TYPE="REFERENCE">Costagliola 1994</LINK>; <LINK REF="REF-Salmon_x002d_Ceron-1995" TYPE="REFERENCE">Salmon-Ceron 1995</LINK>; <LINK REF="REF-Delanghe--1998" TYPE="REFERENCE">Delanghe 1998</LINK>; <LINK REF="REF-De-Monye-1999" TYPE="REFERENCE">De Monye 1999</LINK>). The survival analysis was not adjusted for baseline clinical stage of disease, degree of immunosuppression, and viral burden of the individual subjects in any of these reports and studies. In contrast, another study reports that low-dose iron supplementation did not increase HIV-1 load (<LINK REF="STD-Olsen-2004" TYPE="STUDY">Olsen 2004</LINK>).</P>
<P>Currently, iron supplementation for anaemic infants and children is routinely practiced without any obvious effect in developing countries, which bear most of the burden of global paediatric HIV infections.</P>
<P>Because iron deficiency and IDA are common in HIV-infected children in high-prevalence areas and because there are concerns over a possible deleterious effect of iron, this review aims to assess the evidence for iron supplementation for reducing morbidity and mortality in HIV-infected children.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-11-11 11:41:51 -0800" MODIFIED_BY="[Empty name]">
<P>To determine the safety and efficacy of iron supplementation in improving clinical, immunologic, and virologic outcomes in children infected with HIV</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-11 12:55:23 -0800" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-11-11 11:33:10 -0800" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P> All randomized controlled clinical trials that compare iron supplementation with other products and/or placebo.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Children aged 12 years and below with human immunodeficiency virus infection, from hospital or out-patient (ambulatory) settings. Children may be receiving HAART.</P>
<P>All studies of children with bleeding disorders will be excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Iron supplementation in any form, dosage and administered by any route for all durations</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-11 11:33:10 -0800" MODIFIED_BY="[Empty name]">
<P>Primary Outcomes<BR/>-Safety<BR/>
</P>
<UL>
<LI>Mortality</LI>
<LI>Progression to AIDS,measured by the incidence of AIDS defining illnesses (clinical definition) and by CD4% and/or absolute CD4 counts (immunologic definition).</LI>
</UL>
<P>
<BR/>Secondary outcomes<BR/>-Efficacy<BR/>
</P>
<UL>
<LI>Change in CD4 counts, measured as the mean of absolute changes over time and change across immune categories.</LI>
<LI>Change in viral load over time will be measured in logs. A 2 log change in viral load will be considered significant between measured periods.</LI>
<LI>Number of hospital admissions will be measured as number of admissions over period of follow-up.</LI>
<LI>Duration of hospitalization. The mean duration will be measured.</LI>
<LI>Need for blood transfusions will be recorded as the number of transfusions needed and mean volume of blood required during study period.</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-11 12:54:05 -0800" MODIFIED_BY="[Empty name]">
<P>See: Cochrane HIV/AIDS Group methods used in reviews.<BR/>See: HIV/AIDS Collaborative Review Group search strategy.</P>
<P>With the assistance of the HIV/AIDS Review Group Trials Search co-coordinator, we formulated a comprehensive and exhaustive search strategy in an attempt to identify all relevant studies regardless of language or publication status (published, unpublished, in press, and in progress). Full details of the Cochrane HIV/AIDS Review Group methods and the journals handsearched are published in <I>The Cochrane Library </I>in the section on Cochrane Collaborative Groups (http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/HIV/frame.html).</P>
<P>We used the RCT search strategy developed by The Cochrane Collaboration and detailed in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> in combination with terms specific to iron deficiency.</P>
<P>The following electronic databases were searched</P>
<UL>
<LI>MEDLINE (1966 to date) via PUBMED in September 2007 and updated in November 2007 using the strategy described in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>
</LI>
</UL>
<P>This search yielded 89 references from which we selected three for full article retrieval.</P>
<UL>
<LI>EMBASE (1980 to 2007) in December 2007 using the strategy described in <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>. This search yielded 38 references from which we selected two for full text retrieval.</LI>
</UL>
<UL>
<LI>We also searched NLM Gateway and AIDSearch, which includes coverage of the following conferences:</LI>
</UL>
<P>-International AIDS Conferences (1985 to date)<BR/>-Conference on Retroviruses and Opportunistic Infections (1986 to date)<BR/>-The British HIV Association conference (1997 to date)<BR/>-International Congress on Drug Therapy in HIV infection (1994 to date)</P>
<UL>
<LI>Searching AIDSearch (1980-2007) in December 2007 using the search strategy described in <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK> yielded 60 records, of which we selected three for full article retrieval. Searching the NLM Gateway (1980-2007) in December 2007 using the strategy shown in <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK> yielded 13 records, but none were selected for full article retrieval.</LI>
</UL>
<UL>
<LI>The Cochrane Controlled Trials Register, published in The Cochrane Library (the latest issue available at the time) using the search strategy described in <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>. This contains mainly reference information specific to randomised control trials and controlled clinical trials in healthcare. This yielded 6 references in total of which we selected 2 for full article review.</LI>
</UL>
<P>There was some overlap between references retrieved in each database. We also checked the citations of all the trials identified by our search strategy for relevant studies.</P>
<P>The clinical registers (ClinicalTrials.gov and Current Controlled Trials) were also searched. No additional ongoing studies were found.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-11-11 12:55:23 -0800" MODIFIED_BY="[Empty name]">
<P>Reviewers IMOA and UO independently screened and selected abstracts of all records identified for eligibility. Description of interventions, study design, available outcomes, and clinical data were extracted from the abstract using a brief, standardised eligibility form. Studies were rejected on initial screening if they were not RCTs with at least one comparison group of non-supplemented children.</P>
<P>Agreement between the two reviewers was reached by discussion with the HIV/AIDS Mentor (NS) acting as final arbiter in case of disagreement. Full papers were then obtained for all abstracts passing the initial screening and for records in which eligibility was uncertain. These papers were then assessed for eligibility in more detail and classified according to the review objectives.</P>
<P>The major headings in the standardised data extraction form included the following.</P>
<UL>
<LI>
<U>Administrative details</U>: identification; authors; published or unpublished; year of publication; number of studies included in paper; year in which study was conducted; details of other relevant papers cited.</LI>
<LI>
<U>Details of study</U>: study design;type, duration and completeness of follow-up; country and location of study (developed versus developing country).</LI>
<LI>
<U>Characteristics of participants</U>: prior exposure to antiretroviral therapy (type and duration); disease stage; baseline CD4 count; baseline HIV RNA level.</LI>
<LI>
<U>Details of intervention</U>: types and doses of drugs used; duration of therapy; adverse events (methods of surveillance for adverse events and type: minor or severe) and adherence measures (if reported).</LI>
</UL>
<P>
<BR/>No RCTs met the inclusion criteria. The reasons for exclusion of retrieved full text articles are given in the table of excluded studies. However, should any trials meet the inclusion criteria in the future, we will assess quality and extract and analyse data as described in this section.</P>
<P>
<I>Quality Assessment </I>
<BR/>We planned to qualitatively capture trial methods by recording the method of generating the randomisation sequence; the adequacy of allocation concealment; the adequacy of blinding in the participants, providers and assessors; and the differential loss-to-follow-up in the comparison groups. Had we found any trial, we would not have quantified trial quality using a scale but would have described it in full, where applicable.</P>
<P>Usually there is significant heterogeneity between clinical trials examining the same intervention. Had we found any studies, we would have grouped participants by clinical categories or disease stage according to the World Health Organization (WHO) (<LINK REF="REF-WHO-2006" TYPE="REFERENCE">WHO 2006</LINK>), as shown in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> or Centers for Disease Control and Prevention (CDC) 1994 revised HIV paediatric classification system criteria (<LINK REF="REF-CDC-1994" TYPE="REFERENCE">CDC 1994</LINK>), as seen in Table 2. Hospital-based in-patient studies would have been considered separately from studies performed in ambulatory patients. We would have grouped people on highly active antiretroviral therapy (HAART) differently from those yet to commence HAART. We would have utilized a Chi-square test for homogeneity to test between-trial heterogeneity and the I-squared test to quantify the degree of heterogeneity. If we had found significant heterogeneity, the results would have been considered non-comparable, and we would not have performed a meta-analysis. If subgrouped studies were relatively homogeneous and it was possible to combine trial results in a meta-analysis, a random effects method would have been used. For binary outcomes, we would have calculated treatment effect as relative risks and calculated the 95% confidence intervals. For continuous outcomes, treatment effects would have been calculated as weighted mean differences, while for survival analysis, they would have been combined using the generic inverse variance. We also would have made estimates of hazard ratios where this data was provided in useable format.<BR/>
</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-11 12:02:25 -0800" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION>
<P>No studies were identified that fulfilled the selection criteria</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>No studies were identified that fulfilled the selection criteria.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-11 12:02:25 -0800" MODIFIED_BY="[Empty name]">
<P>This review has no analyses</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-11-11 12:54:58 -0800" MODIFIED_BY="[Empty name]">
<P>In this review, no RCTs on the effectiveness of iron supplementation in reducing morbidity and mortality in HIV-infected children were found.</P>
<P>Although there have been several trials of iron supplementation in HIV-uninfected children, a systematic review with Cochrane-style methodology also is lacking. There was one non-Cochrane review of oral iron supplementation in non-HIV-infected children aged to 59 months who live in developing countries to ascertain the associated health benefits and risks (<LINK REF="REF-Iannotti-2006" TYPE="REFERENCE">Iannotti 2006</LINK>). In this review of 26 RCTs, varied primary outcomes were considered and there was sufficient evidence for benefits with respect to cognitive function, motor development, recovery from anaemia, and prevention of anaemia. Presupplementation iron stores and anaemia appeared to act as effect modifiers. The evidence providing support for the role of baseline iron indices and anaemia were that clear benefits followed supplementation of iron-deficient and anaemic children and the reports of adverse events related to malaria-related morbidity and poor weight gain in iron-replete children. Current practice of iron supplementation in HIV-infected adults and children is based on observational studies, especially those reporting the baseline haematological status and indices of iron storage in HIV-infected persons, including children (<LINK REF="REF-Eley--2002" TYPE="REFERENCE">Eley 2002</LINK>; <LINK REF="REF-Totin--2002" TYPE="REFERENCE">Totin 2002</LINK>; <LINK REF="REF-Adetifa-2006" TYPE="REFERENCE">Adetifa 2006</LINK>); those that report no evidence for deleterious effects of iron ( <LINK REF="REF-Semba-2001" TYPE="REFERENCE">Semba 2001</LINK>;<LINK REF="REF-Kupka-2007" TYPE="REFERENCE">Kupka 2007</LINK>; <LINK REF="STD-Semba-2007" TYPE="STUDY">Semba 2007</LINK>); and others that observed development of opportunistic infection and the progression of HIV disease (<LINK REF="REF-Weinberg-1996" TYPE="REFERENCE">Weinberg 1996</LINK>; <LINK REF="REF-Sahli-1998" TYPE="REFERENCE">Sahli 1998</LINK>; <LINK REF="REF-Gordeuk-2006" TYPE="REFERENCE">Gordeuk 2006</LINK>).</P>
<P>There is an urgent need to conduct RCTs of iron supplementation in HIV-infected children, especially those resident in malarious areas and other parts of the world with significant overlap between prevalence of iron- and non-iron-related anaemia to provide high-quality evidence for the effectiveness of this intervention. It is key for studies to be done in settings with high burdens of paediatric HIV/AIDS and iron deficiency and iron deficiency anaemia. Ideally, these trials should include children of ages from infancy to adolescence and children already on HAART. It also will be important for these studies to conduct baseline and serial assessments of iron storage indices and haemoglobin, as these are likely effect modifiers. The outcomes of these trials must be adjusted for clinical and immunologic classification of the study population at diagnosis of HIV and also for viral loads. At the same time, it will be important to obtain evidence from unbiased reviews of trials of iron supplementation in HIV-uninfected children in malarious and non-malarious areas to obtain some comparative data for a normal population of children. Completion of a number of Cochrane reviews in progress (<LINK REF="REF-Martins-2001" TYPE="REFERENCE">Martins 2001</LINK>; <LINK REF="REF-Fraser-2006" TYPE="REFERENCE">Fraser 2006</LINK>; <LINK REF="REF-Xiaoxi-2007" TYPE="REFERENCE">Xiaoxi 2007</LINK>; <LINK REF="REF-Ojukwu-2007" TYPE="REFERENCE">Ojukwu 2007</LINK>) will assist with gathering this evidence. Apart from ensuring that evidence is collected from varied geographic settings, it is important that trials are adequately powered to examine results related to clinical outcomes, including growth, mental and physical development, haematologic profiles, susceptibility to infections, and ease of supplementation, as well as virologic and immunologic outcomes.</P>
<P>It is important to highlight key ethical and logistic issues and questions that may arise if these trials are to be conducted properly. It may be argued that HIV-infected children with clinical or laboratory features, or both, of iron deficiency or anaemia should be promptly treated, in view of the benefits of iron supplementation to overall mental and physical growth, and therefore not randomised to a placebo or non-iron supplementation arm of any trial. However, until there is incontrovertible evidence for or against a deleterious effect of iron on viral and immunologic outcomes, especially in this era of HAART, it will be unclear if iron supplementation falls within the ambits of acts of maleficence or beneficence in HIV-infected children and adults. Reports of resolution or improvement of anaemia in HIV-infected persons on HAART without supplementation further complicates issues of trial design and interpretation (<LINK REF="REF-Berhane-2004" TYPE="REFERENCE">Berhane 2004</LINK>). It is common knowledge that HIV infection is associated with a chronic inflammatory response attributed both to the virus and to opportunistic infections that may be present. Serum ferritin and plasma transferrin receptor concentration (common parameters for assessing body iron status) are affected by the acute-phase response (<LINK REF="REF-Semba-2000" TYPE="REFERENCE">Semba 2000</LINK>; <LINK REF="REF-Weinberg-2001" TYPE="REFERENCE">Weinberg 2001</LINK>). Therefore, baseline and serial measurements of other acute phase reactants, such as C-reactive protein and alpha1-antichymotrypsin, must be performed, and where these suggest an ongoing acute-phase response, outcome data may have to be adjusted for the acute-phase reaction or even excluded. Obviously, this may lead to biased results or an inadequately powered study if these possibilities are not considered during the design of clinical trials.</P>
<P>Investigating the effectiveness of iron supplementation in HIV-infected children and adults is of particular relevance to developing world settings where the burden of HIV is highest because supplementation is a relatively simple intervention that readily can be translated into practice. This also applies to studies analysing supplementation with other micronutrients.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-11-11 12:23:47 -0800" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2008-11-11 12:21:53 -0800" MODIFIED_BY="[Empty name]">
<P>The current clinical practice of iron supplementation in HIV-infected children is based on weak evidence comprising observational studies and expert opinions.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-11-11 12:23:47 -0800" MODIFIED_BY="[Empty name]">
<P>High-quality RCTs of iron supplementation are required in children who live in areas with significant overlap of high prevalence of HIV, malaria, and IDA. Policy makers should give priority to and allocate funds for such studies. Clinical and community settings with significant paediatric HIV cohorts are most appropriate settings for these studies.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-11-11 12:24:58 -0800" MODIFIED_BY="[Empty name]">
<P>We acknowledge the assistance of the South African Cochrane Centre and Cochrane HIV/AIDS Review Group Mentoring Programme.<BR/>Nandi Siegfried provided mentorship to Ifedayo Adetifa. We are indebted to Joy Oliver for her patience and friendliness in providing support and dealing with all our queries as well as for our literature search.<BR/>We thank Elizabeth Pienaar for her help in putting together our search strategy and with the actual search.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS/>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacobus-1996" NAME="Jacobus 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jacobus DP</AU>
<TI>Randomization to iron supplementation of patients with advanced human immunodeficiency virus disease-an inadvertent but controlled study with results important for patient care</TI>
<SO>J Infect Dis</SO>
<YR>1996</YR>
<VL>173</VL>
<PG>1044-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olsen-2004" NAME="Olsen 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olsen A, Mwaniki D, Krarup H, Friis H</AU>
<TI>Low-dose iron supplementation does not increase HIV-1 load</TI>
<SO>Journal of Acquired Immune Deficiency Syndrome</SO>
<YR>2004</YR>
<VL>36</VL>
<NO>1</NO>
<PG>637-638</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olsen-2006" NAME="Olsen 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olsen A, Nawiri J, Magnussen P, Krarup H, Friis H</AU>
<TI>Failure of twice-weekly iron supplementation to increase blood haemoglobin and serum ferritin concentrations: results of a randomized controlled trial</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>2006</YR>
<VL>100</VL>
<NO>3</NO>
<PG>251-263</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Semba-2007" NAME="Semba 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Semba RD, Ricketts EP, Mehta S, Netski D, Thomas D, Kirk G</AU>
<TI>Eefect of micronutrients and iron supplementation on haemoglobin, iron status, and plasma hepatitis C and HIV RNA levels in female injection drug users: a controlled clinical trial</TI>
<SO>J Acquir Immune Defic Syndr</SO>
<YR>2007</YR>
<VL>45</VL>
<PG>298-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Adetifa-2006" NAME="Adetifa 2006" NOTES="&lt;p&gt;1. Adetifa IMO, Temiye EO, Akinsulie AO, Ezeaka VC, Iroha EO. Haematolgical abnormalities associated with paediatric HIV/AIDS in Lagos. Ann Trop Paediatr 2006;26:121-5.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Adetifa IMO, Temiye EO, Akinsulie AO, Ezeaka VC, Iroha EO</AU>
<TI>Haematolgical abnormalities associated with paediatric HIV/AIDS in Lagos</TI>
<SO>Annals Tropical Paediatrics</SO>
<YR>2006</YR>
<VL>26</VL>
<PG>121-125</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Adewuyi-1994" NAME="Adewuyi 1994" TYPE="JOURNAL_ARTICLE">
<AU>Adewuyi J, Chitsike I</AU>
<TI>Haematologic features of the human immunodeficiency virus (HIV) infection in black children in Harare</TI>
<SO>Central Africa Journal of Medicine</SO>
<YR>1994</YR>
<VL>40</VL>
<PG>333-336</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Afacan--2002" NAME="Afacan  2002" NOTES="&lt;p&gt;2. Afacan YE, Hasan MS, Omene JA. Iron deficiency anaemia in HIV infection: immunologic and virologic response. J Natl Med Assoc 2002;94(2):73-7.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Afacan YE, Hasan MS, Omene JA</AU>
<TI>Iron deficiency anaemia in HIV infection: immunologic and virologic response</TI>
<SO>Journal of the National Medical Association</SO>
<YR>2002</YR>
<VL>94</VL>
<NO>2</NO>
<PG>73-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allen-1998" NAME="Allen 1998" NOTES="&lt;p&gt;3. Allen UD, King SM, Gomez MP, et al. Serum immunoreactive erythropoietin levels and associated factors amongst HIV-infected children. AIDS 1998;12:1785-1791.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Allen UD, King SM, Gomez MP, et al</AU>
<TI>Serum immunoreactive erythropoietin levels and associated factors amongst HIV-infected children</TI>
<SO>AIDS</SO>
<YR>1998</YR>
<VL>12</VL>
<PG>1785-1791</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berhane-2004" NAME="Berhane 2004" TYPE="JOURNAL_ARTICLE">
<AU>Berhane K, Karim R, Cohen MH, Masri-Lavine L, Young M, Anastos K, Augenbraun M, WattsDH, Levine AM</AU>
<TI>Impact of highly active antiretroviral therapy on anaemia and relationship between anaemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study</TI>
<SO>J Acquir Immune Defic Syndr</SO>
<YR>2004</YR>
<VL>37</VL>
<PG>1245-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boelaert--1996" NAME="Boelaert  1996" NOTES="&lt;p&gt;4. Boelaert JR, Weinberg GA, Weinberg ED. Altered iron metabolism in HIV infection:mechanisms, possible consequences, and proposals for management. Infect Agents Dis 1996;5:36-46.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Boelaert JR, Weinberg GA, Weinberg ED</AU>
<TI>Altered iron metabolism in HIV infection:mechanisms, possible consequences, and proposals for management</TI>
<SO>Infect Agents Dis</SO>
<YR>1996</YR>
<VL>5</VL>
<PG>36-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Butler-1991" NAME="Butler 1991" TYPE="JOURNAL_ARTICLE">
<AU>Butler KM, Husson RN, Balis FM, et al</AU>
<TI>Dideoxyinosine in children with symptomatic HIV infection</TI>
<SO>New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>324</VL>
<PG>137-144</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carr-1998" NAME="Carr 1998" NOTES="&lt;p&gt;5. Carr JM, Ramshaw HS, Li P, Burrell CJ. CD34+ cells and their derivatives contain mRNA for CD4 and HIV co-receptors and are susceptible to infection with M- and T-topic HIV. J Gen Virol 1998;79:71-75.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Carr JM, Ramshaw HS, Li P, Burrell CJ</AU>
<TI>CD34+ cells and their derivatives contain mRNA for CD4 and HIV co-receptors and are susceptible to infection with M- and T-topic HIV</TI>
<SO>Journal of General Virology</SO>
<YR>1998</YR>
<VL>79</VL>
<PG>71-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CDC-1994" NAME="CDC 1994" TYPE="JOURNAL_ARTICLE">
<AU>Centres for Disease Control and Prevention</AU>
<TI>1994 revised classification for human immunodeficiency virus infection in children less than 13 years of age.</TI>
<SO>Morbidity and Mortality Weekly Review</SO>
<YR>1994</YR>
<VL>43</VL>
<NO>RR-12</NO>
<PG>1-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clark--2001" NAME="Clark  2001" NOTES="&lt;p&gt;update full text title according to style guide&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Clark TD, Semba RD</AU>
<TI>Iron supplementaion during human immunodeficiency virus infection: a double-edged sword?</TI>
<SO>Med Hypotheses</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>4</NO>
<PG>476-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clark--2002" NAME="Clark  2002" NOTES="&lt;p&gt;7. Clark TD, Mmiro F, Ndugwa C, et al. Risk factors and cummulative incidence of anaemia among human immunodeficiency virus-infected children in Uganda. Ann Trop Paediatr 2002;22:11-17.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Clark TD, Mmiro F, Ndugwa C, et al</AU>
<TI>Risk factors and cummulative incidence of anaemia among human immunodeficiency virus-infected children in Uganda</TI>
<SO>Annals of Tropical Paediatrics</SO>
<YR>2002</YR>
<VL>22</VL>
<PG>11-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Costagliola-1994" NAME="Costagliola 1994" NOTES="&lt;p&gt;8. Costagliola DG, Montalembert M, Lefrere JJ. Dose od deferroxamine and evolution of HIV-1 infection in thalassaemic patients. Brit J Hematol 1994;87:849-852.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Costagliola DG, Montalembert M, Lefrere JJ</AU>
<TI>Dose of deferroxamine and evolution of HIV-1 infection in thalassaemic patients</TI>
<SO>British Journal of Hematology</SO>
<YR>1994</YR>
<VL>87</VL>
<PG>849-852</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coyle-1997" NAME="Coyle 1997" NOTES="&lt;p&gt;update journal titles according to style guide&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Coyle TE</AU>
<TI>Hematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome</TI>
<SO>Med Clin N Am</SO>
<YR>1997</YR>
<VL>81</VL>
<PG>449-470</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Monye-1999" NAME="De Monye 1999" NOTES="&lt;p&gt;10. De Monye C, Karcher DS, Boelaert JR, Gordeux VR. Bone marrow macrophage iron grade and survival of HIV-seropositive patients. AIDS 1999;13:375-380.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>De Monye C, Karcher DS, Boelaert JR, Gordeux VR</AU>
<TI>Bone marrow macrophage iron grade and survival of HIV-seropositive patients</TI>
<SO>Acquired Immune Deficiency Syndrome</SO>
<YR>1999</YR>
<VL>13</VL>
<PG>375-380</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Delanghe--1998" NAME="Delanghe  1998" NOTES="&lt;p&gt;11. Delanghe JR, Langlois MR, Boelaert JR. Haptoglobin polymorphism, iron metabolism and mortality in HIV infection. AIDS 1998;12:1027-1032.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Delanghe JR, Langlois MR, Boelaert JR</AU>
<TI>Haptoglobin polymorphism, iron metabolism and mortality in HIV infection</TI>
<SO>Acquired Immune Deficiency Syndrome</SO>
<YR>1998</YR>
<VL>12</VL>
<PG>1027-1032</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eley--2002" NAME="Eley  2002" NOTES="&lt;p&gt;12. Eley BS, Sive AA, Shuttleworth M, Hussey GD. A prospective, cross-sectional study of anaemia and peripheral iron status in antiretroviral naive, HIV-1 infected children in Cape Town, South Africa. BMC Infectious Diseases 2002;2(3).&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Eley BS, Sive AA, Shuttleworth M, Hussey GD</AU>
<TI>A prospective, cross-sectional study of anaemia and peripheral iron status in antiretroviral naive, HIV-1 infected children in Cape Town, South Africa</TI>
<SO>BMC Infectious Diseases</SO>
<YR>2002</YR>
<VL>2</VL>
<NO>3</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ellaurie-1990" NAME="Ellaurie 1990" TYPE="JOURNAL_ARTICLE">
<AU>Ellaurie M, Burn ER, Rubinstein A</AU>
<TI>Haematologic manifestations in paediatric HIV infection:severe anaemia as a prognostic factor.</TI>
<SO>Am J Pediatr Hematol Oncol</SO>
<YR>1990</YR>
<VL>12</VL>
<PG>449-453</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feelders--1999" NAME="Feelders  1999" NOTES="&lt;p&gt;13. Feelders RA, Kuiper EPA-Kramer, van Eijk HG. Structure, function and clinical significance of transferrin receptors. Clin Chem Lab Med 1999;37:1-10.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Feelders RA, Kuiper EPA-Kramer, van Eijk HG</AU>
<TI>Structure, function and clinical significance of transferrin receptors</TI>
<SO>Clin Chem Lab Med</SO>
<YR>1999</YR>
<VL>37</VL>
<PG>1-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Forsyth-1996" NAME="Forsyth 1996" TYPE="JOURNAL_ARTICLE">
<AU>Forsyth BN, Andiman WA, O'Connor T</AU>
<TI>Development of a prognosis based clinical staging system for infants infected with human immunodefiency virus</TI>
<SO>J Pediatr</SO>
<YR>1996</YR>
<VL>129</VL>
<PG>648-655</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fraser-2006" NAME="Fraser 2006" TYPE="COCHRANE_REVIEW">
<AU>Fraser A, Bilenko N, Paul M, Leibovici L, Fraser D</AU>
<TI>Supplementation with two or more micronutrients versus single micronutrient supplementation or placebo in young children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Friis-2005" NAME="Friis 2005" TYPE="OTHER">
<AU>Friis H</AU>
<TI>Micronutrients and HIV infection: a review of current evidence</TI>
<SO>Consultation on Nutrition and HIV/AIDS in Africa: evidence, lessons and recommedations for action. World Health Organization. Department of Nutrition for Health and Development</SO>
<YR>2005</YR>
<PG>1-28</PG>
<PB>World Health Organization. Geneva</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Geissler-1991" NAME="Geissler 1991" NOTES="&lt;p&gt;14. Geissler RG, Ottman OG, Eder M, Kojouharoff G, Hoelzer D, Ganser A. Effect of recombinant human transforming growth factor beta and tumour necrosis factor alpha on bone marrow progenitor cells of HIV-infected persons. Ann Hematol 1991;62:151-155.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Geissler RG, Ottman OG, Eder M, Kojouharoff G, Hoelzer D, Ganser A</AU>
<TI>Effect of recombinant human transforming growth factor beta and tumour necrosis factor alpha on bone marrow progenitor cells of HIV-infected persons</TI>
<SO>Ann Hematol</SO>
<YR>1991</YR>
<VL>62</VL>
<PG>151-155</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gordeuk-2006" NAME="Gordeuk 2006" TYPE="JOURNAL_ARTICLE">
<AU>Gordeuk VR, Onojobi G, Schneider MF, Dawkins FW, Delapenha R, Voroshin Y, von Wyl V, Bacon M, Minkoff H, Levine A, Cohen M, Greenblatt RM</AU>
<TI>The association of serum ferritin and transferrin receptor concentrations with mortality in women with human immunodeficiency virus infection</TI>
<SO>Haematologica</SO>
<YR>2006</YR>
<VL>91</VL>
<PG>739-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gordeux-2001" NAME="Gordeux 2001" NOTES="&lt;p&gt;15. Gordeux VR, Delanghe JR, Langlois MR, Boelaert JR. Iron status and the outcome of HIV infection: an overview. J Clin Virol 2001;20:111-5.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Gordeux VR, Delanghe JR, Langlois MR, Boelaert JF</AU>
<TI>Iron status and the outcome of HIV infection: an overview</TI>
<SO>J Clin Virol</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>111-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Iannotti-2006" NAME="Iannotti 2006" TYPE="JOURNAL_ARTICLE">
<AU>Iannotti LL, Tielsch JM, Black MM, Black RE</AU>
<TI>Iron supplementation in early childhood: heatlh benefits and risks</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2006</YR>
<VL>84</VL>
<PG>1261-1276</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kupka-2007" NAME="Kupka 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kupka R, Msamanga GI, Mugusi F, Petraro P, Hunter DJ, Fawzi WW</AU>
<TI>Iron status is an important cause of anaemia in HIV infected Tanzanian women but is not related to accelerated HIV disease progression</TI>
<SO>J Nutr</SO>
<YR>2007</YR>
<VL>137</VL>
<PG>2317-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martins-2001" NAME="Martins 2001" TYPE="COCHRANE_REVIEW">
<AU>Martins S, Logan S, Gilbert R</AU>
<TI>Iron supplementation for improving psychomotor development and cognitive function in infants under the age of one</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McDermid-2007" NAME="McDermid 2007" TYPE="JOURNAL_ARTICLE">
<AU>McDermid JM, Jaye A, Schim van der Loeff MF, Todd J, Austin S, Jeffries D, Awasana AA, Whittlex AA, Prentice AA</AU>
<TI>Elevated iron status strongly predicts mortality in West African adults with HIV infection</TI>
<SO>J Acquir Immune Defic Syndrom</SO>
<YR>2007</YR>
<VL>46</VL>
<PG>498-507</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1999" NAME="Moore 1999" NOTES="&lt;p&gt;16. Moore RD. Human immunodeficiency virus infection, anaemia and survival. Clin Infect Dis 1999;29:44-9.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Moore RD</AU>
<TI>Human immunodeficiency virus infection, anaemia and survival</TI>
<SO>Clin Infect Dis</SO>
<YR>1999</YR>
<VL>29</VL>
<PG>44-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moses-1996" NAME="Moses 1996" NOTES="&lt;p&gt;17. Moses AV, Williams S, Heneveld ML. Human immunodeficiency virus infection of the bone marrow epithelium reduces induction of stromal hematopoietic growth factors. Blood 1996;87:919-925.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Moses AV, Williams S, Heneveld ML</AU>
<TI>Human immunodeficiency virus infection of the bone marrow epithelium reduces induction of stromal hematopoietic growth factors</TI>
<SO>Blood</SO>
<YR>1996</YR>
<VL>87</VL>
<PG>919-925</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ojukwu-2007" NAME="Ojukwu 2007" TYPE="COCHRANE_REVIEW">
<AU>Ojukwu JU, Okebe JU</AU>
<TI>Routine iron supplementation for preventing or treating iron-deficiency anaemia in children in malaria-endemic areas</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olsen-2004" NAME="Olsen 2004" NOTES="&lt;p&gt;18. Olsen A, Mwanniki D, Krarup H, Friis H. Low-dose iron supplementation does not increase HIV-1 load. J Acquir Immune Defic Syndr 2004;36:637-638.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Olsen A, Mwanniki D, Krarup H, Friis H</AU>
<TI>Low-dose iron supplementation does not increase HIV-1 load</TI>
<SO>J Acquir Immune Defic Syndr</SO>
<YR>2004</YR>
<VL>36</VL>
<PG>637-638</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pizzo-1988" NAME="Pizzo 1988" TYPE="JOURNAL_ARTICLE">
<AU>Pizzo PA, Eddy J, Falloon J, et al</AU>
<TI>Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection</TI>
<SO>N Engl J Med</SO>
<YR>1988</YR>
<VL>319</VL>
<PG>889-896</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Richman-1987" NAME="Richman 1987" NOTES="&lt;p&gt;19. Richman D, AZT Collaborative Working Group. The toxicity of azidothymidine in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317:192.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Richman D, AZT Collaborative Working Group</AU>
<TI>The toxicity of azidothymidine in the treatment of patients with AIDS and AIDS-related complex</TI>
<SO>N Engl J Med</SO>
<YR>1987</YR>
<VL>317</VL>
<PG>192</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sahli-1998" NAME="Sahli 1998" TYPE="JOURNAL_ARTICLE">
<AU>Sahli Y, Costagliola DG, Rebulla P, et al</AU>
<TI>Serum ferritin, desferrioxamine, and evolution of HIV-1 infection in thalassemic patients.</TI>
<SO>J Acquir Immune Defic Syndr Hum Retrovirol</SO>
<YR>1998</YR>
<VL>18</VL>
<PG>473-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salmon_x002d_Ceron-1995" NAME="Salmon-Ceron 1995" NOTES="&lt;p&gt;20. Salmon-Ceron D, Fontbonne A, J S. Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. J Infect Dis 1995;172:656-664.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Salmon-Ceron D, Fontbonne A, Saba J</AU>
<TI>Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia</TI>
<SO>J Infect Dis</SO>
<YR>1995</YR>
<VL>172</VL>
<PG>656-664</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savarino-1999" NAME="Savarino 1999" NOTES="&lt;p&gt;21. Savarino A, Pescarmona GP, Boelaert JR. Iron metabolism and HIV infection:reciprocal interactions with potentially harmful consequences? Cell Biochem Funct 1999;17:279-287.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Savarino A, Pescarmona GP, Boelaert JR</AU>
<TI>Iron metabolism and HIV infection:reciprocal interactions with potentially harmful consequences?</TI>
<SO>Cell Biochem Funct</SO>
<YR>1999</YR>
<VL>17</VL>
<PG>279-287</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schwartz--1994" NAME="Schwartz  1994" NOTES="&lt;p&gt;22. Schwartz GN, Kessler SW, Rothwell SW. Inhibitory effects of HIV-1-infected stromal cell layers on production of myeloid progenitor cels in human long-term bone marrow cultures. Exp Hematol 1994;22:1288-1296.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz GN, Kessler SW, Rothwell SW</AU>
<TI>Inhibitory effects of HIV-1-infected stromal cell layers on production of myeloid progenitor cels in human long-term bone marrow cultures</TI>
<SO>Exp Hematol</SO>
<YR>1994</YR>
<VL>22</VL>
<PG>1288-1296</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Semba--2003" NAME="Semba  2003" NOTES="&lt;p&gt;24. Semba RD. Iron-deficiency anaemia and the cycle of poverty among human imunodeficiency virus-infected women in the inner city. Clin Infect Dis 2003;37(Suppl 2):S105-11.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Semba RD</AU>
<TI>Iron-deficiency anaemia and the cycle of poverty among human imunodeficiency virus-infected women in the inner city</TI>
<SO>Clin Infect Dis</SO>
<YR>2003</YR>
<VL>37</VL>
<NO>Suppl 2</NO>
<PG>S105-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Semba-2000" NAME="Semba 2000" TYPE="JOURNAL_ARTICLE">
<AU>Semba RD, Kumwenda N, Hoover DR, Taha TE, Mtimavalye L, Broadhead R, Eisinger W, Miotti PG, Chiphangwi JD</AU>
<TI>Assessment of iron status using plasma transferrin receptor in pregnant women with and without human immunodeficiency virus infection in Malawi</TI>
<SO>Eur J Clin Nutr</SO>
<YR>2000</YR>
<VL>54</VL>
<PG>872-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Semba-2001" NAME="Semba 2001" NOTES="&lt;p&gt;23. Semba RD, Gray GE. The pathogenesis of anaemia during human immunodeficiency virus infection. J Invest Med 2001;49:225-239.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Semba RD, Gray GE</AU>
<TI>The pathogenesis of anaemia during human immunodeficiency virus infection</TI>
<SO>J Invest Med</SO>
<YR>2001</YR>
<VL>49</VL>
<PG>225-239</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Semba-2007" NAME="Semba 2007" TYPE="JOURNAL_ARTICLE">
<AU>Semba RD, Ricketts EP, Mehta S, Netski D, Thomas D, Kirk G, Wu AW, Vlahov D</AU>
<TI>Effect of micronutrients and riron supplementation on haemoglobin, iron status, and plasma hepatitis C and HIV RNA levels in female injection drug users: a controlled clinical trial</TI>
<SO>J Acquir Immune Defic Syndr</SO>
<YR>2007</YR>
<VL>45</VL>
<PG>298-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Totin--2002" NAME="Totin  2002" NOTES="&lt;p&gt;25. Totin D, Ndugwa C, Mmiro F, Perry RT, Jackson JB, Semba RD. Iron deficiency anaemia is highly prevalent among human immunodeficiency virus-infected and uninfected infants in Uganda. J Nutr 2002;132:423-9.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Totin D, Ndugwa C, Mmiro F, Perry RT, Jackson JB, Semba RD</AU>
<TI>Iron deficiency anaemia is highly prevalent among human immunodeficiency virus-infected and uninfected infants in Uganda</TI>
<SO>J Nutr</SO>
<YR>2002</YR>
<VL>132</VL>
<PG>423-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-UNICEF-1998" NAME="UNICEF 1998" TYPE="OTHER">
<AU>UNICEF/UNU/WHO/MI</AU>
<TI>Preventing iron deficiency in women and children: background and consensus on key technical issues and resources for advocacy, planning, and implementing national programs</TI>
<SO>UNICEF/UNU/WHO/MI Technical Workshop, 1998</SO>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Volberding--2000" NAME="Volberding  2000" NOTES="&lt;p&gt;26. Volberding P. Consensus statement:anaemia in HIV infection-current trends, treatment options, and practice strategies. Clin Ther 2000;22:1004-1020.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Volberding P</AU>
<TI>Consensus statement:anaemia in HIV infection-current trends, treatment options, and practice strategies</TI>
<SO>Clin Ther</SO>
<YR>2000</YR>
<VL>22</VL>
<PG>1004-1020</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vorster--2004" NAME="Vorster  2004" NOTES="&lt;p&gt;27. Vorster HH, Kruger A, Margetts BM, et al. The nutritional status of asymptomatic HIV-infected Africans:directions for dietary intervention? Public Health Nutrition 2004;7(8):1055-1064.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Vorster HH, KrugerA, Margetts BM, et al</AU>
<TI>The nutritional status of asymptomatic HIV-infected Africans:directions for dietary intervention?</TI>
<SO>Public Health Nutrition</SO>
<YR>2004</YR>
<VL>7</VL>
<NO>8</NO>
<PG>1055-1064</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weinberg-1996" NAME="Weinberg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Weinberg GA</AU>
<TI>Iron overload as a mechanism for the lowered survival in AIDS patients receiving dapsone-iron protoxolate for secondary prophylaxis of Pneumocystis carinii pneumonia</TI>
<SO>J Infect Dis</SO>
<YR>1996</YR>
<VL>174</VL>
<PG>241-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weinberg-2001" NAME="Weinberg 2001" TYPE="JOURNAL_ARTICLE">
<AU>Weinberg GA, Friis H, Boelaert JR, Weinberg ED</AU>
<TI>Iron status and the severity of HIV infection in pregnant women</TI>
<SO>Clin Infect Dis</SO>
<YR>2001</YR>
<VL>33</VL>
<PG>2098-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2001" NAME="WHO 2001" TYPE="JOURNAL_ARTICLE">
<AU>UNICEF/WHO/UNU</AU>
<TI>Iron Deficiency Anaemic-Assessment, Prevention, and Control. A guide for programme Managers. http//:www.who.int/nutrition/publications/en/ida_assessment_prevention_control.pdf</TI>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2006" NAME="WHO 2006" TYPE="BOOK">
<AU>World Health Organization</AU>
<TI>Antiretroviral therapy of HIV infection in infants and children in resource limited settings:towards universal access. Recommendations for a public health approach</TI>
<YR>2006</YR>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xiaoxi-2007" NAME="Xiaoxi 2007" TYPE="COCHRANE_REVIEW">
<AU>Xiaoxi Z, Wu T</AU>
<TI>Iron supplementation for iron deficiency anaemia in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CD006465"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zauli--1996" NAME="Zauli  1996" NOTES="&lt;p&gt;29. Zauli G, Vitale M, Gibellini D, Capitani S. Inhibition of purified CD34+ hematopoietic progenitor cells by human immunodeficiency virus-1 or gp120 mediated by endogenous transforig growth factor beta-1. J Exp Med 1996;183:99-108.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Zauli G, Vitale M, Gibellini D, Capitani S</AU>
<TI>Inhibition of purified CD34+ hematopoietic progenitor cells by human immunodeficiency virus-1 or gp120 mediated by endogenous transforig growth factor beta-1</TI>
<SO>J Exp Med</SO>
<YR>1996</YR>
<VL>183</VL>
<PG>99-108</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zauli-1994" NAME="Zauli 1994" NOTES="&lt;p&gt;28. Zauli G, Furlini G, Vitale M. A subset of human CD34+ haematopoietic progenitors express low levels of CD4, the high affinity receptor for human immunodeficiency virus-type 1. Blood 1994;84:1896-1905.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Zauli G, Furlini G, Vitale M</AU>
<TI>A subset of human CD34+ haematopoietic progenitors express low levels of CD4, the high affinity receptor for human immunodeficiency virus-type 1</TI>
<SO>Blood</SO>
<YR>1994</YR>
<VL>84</VL>
<PG>1896-1905</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zon-1988" NAME="Zon 1988" NOTES="&lt;p&gt;30. Zon LI, Groopman J. Hematologic manifestations of the human immune deficiency virus (HIV). Seminars in Hematology 1988;25(3):208-218.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Zon LI, Groopman J</AU>
<TI>Hematologic manifestations of the human immune deficiency virus (HIV)</TI>
<SO>Seminars in Hematology</SO>
<YR>1988</YR>
<VL>25</VL>
<NO>3</NO>
<PG>208-218</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Jacobus-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Clinical trial, no randomization, unplanned controlled trial, not in children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Olsen-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT: post-hoc analysis of results from a RCT of iron supplementation done on adults and children. HIV status was not identified at onset of study. HIV testing and viral load were conducted anonymously on samples archived at 4-month follow-up in the original trial. No HIV testing or viral load assessments were done on samples of the children recruited.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Olsen-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of iron supplementation in a mixed adult and children population: HIV status not determined at onset but on a sample of archived adult samples collected at 4-month follow-up. Primary outcomes were blood haemoglobin and serum ferritin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Semba-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Clinical trial of iron and other micronutrients in HIV and Hepatitis C infected female injection drug users</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2008-11-11 12:48:51 -0800" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2008-11-11 12:48:51 -0800" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-11-11 12:36:16 -0800" MODIFIED_BY="[Empty name]">Centers for Diseases Control and Prevention: HIV Paediatric Clinical Categories</TITLE>
<TABLE COLS="4" ROWS="19">
<TR>
<TH>
<P>Category N</P>
</TH>
<TH>
<P>Category A</P>
</TH>
<TH>
<P>Category B</P>
</TH>
<TH>
<P>Category C</P>
</TH>
</TR>
<TR>
<TD>
<P>Children who are asymptomatic of HIV infection or who have only one Category A condition</P>
</TD>
<TD>
<P>Children with 2 or more of the following conditions and no Category B or C condition</P>
</TD>
<TD>
<P>Children who are symptomatic and have conditions like below other than those in Categories A or C</P>
</TD>
<TD>
<P>Serious bacterial infections, multiple or recurrent (e.g. any combination of at least 2 culture-confirmed infections within a 2-year period), of the following types: septicaemia, pneumonia, meningitis, bone or joint infection, or abscess of an internal organ or body cavity (excluding otitis media, superficial skin or mucosal abscesses, and indwelling catheter-related infections)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>-Lymphadenopathy (&gt;0.5cm at &gt;2 sites; bilateral= 1 site)</P>
</TD>
<TD>
<P>Anaemia (&lt;8g/dL), neutropenia (&lt;1000/mm<SUP>3</SUP>), or thrombocytopenia (&lt;100 000/mm<SUP>3</SUP>) persisting &gt;30 days</P>
</TD>
<TD>
<P>Candidiasis, oesophageal, or pulmonary (bronchi, trachea, lungs)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>-Hepatomegaly</P>
</TD>
<TD>
<P>Bacterial meningitis, pneumonia, or sepsis (single episode)</P>
</TD>
<TD>
<P>Coccidiodomycosis, disseminated (at site other than or in addition to lungs or cervical or hilar lymph nodes)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>-Splenomegaly</P>
</TD>
<TD>
<P>Candidiasis, oropharyngeal (e.g. thrush) persisting for &gt;2 months in children &gt;6 months</P>
</TD>
<TD>
<P>Cryptococcosis, extrapulmonary</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>-Dermatitis</P>
</TD>
<TD>
<P>Cardiomyopathy</P>
</TD>
<TD>
<P>Cryptosporidiosis or isosporiasis with diarrhoea persisting &gt;1 month</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>-Parotitis</P>
</TD>
<TD>
<P>Cytomegalovirus (CMV) infection with onset before age 1 month</P>
</TD>
<TD>
<P>CMV disease with onset of symptoms at age &gt;1 month (at a site other than liver, spleen, or lymph nodes)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>-Recurrent or persistent upper respiratory infection, sinusitis, or otitis media</P>
</TD>
<TD>
<P>Diarrhoea, recurrent or chronic</P>
</TD>
<TD>
<P>Encephalopathy (at least 1 of the following progressive findings present for at least 2 months in the absence of concurrent illness other than HIV infection that could explain the findings): a) failure to attain or loss of developmental milestones or loss of intellectul ability, verified by standard developmental scale or neuropsychological tests; b) impaired brain growth or acquired microcephaly demonstrated by head circumference measurements of brain atrophy demonstrated by CT or MRI (serial imaging is required for children age &lt;2 years); c) acquired symmetric motor deficit manifested by 2 or more of the following: paresis, pathologic reflexes, ataxia, or gait disturbance</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Hepatitis</P>
</TD>
<TD>
<P>Herpes simplex virus (HSV) causing a mucocutaneous ulcer that persists for &gt;1 month or bronchitis, pneumonitis, or oesophagitis for any duration affecting a child aged &gt;1 month</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>HSV stomatitis, recurrent (e.g. &gt;2 episodes within 1 year)</P>
</TD>
<TD>
<P>Histoplasmosis, disseminated (at site other than or in addition to lungs or cervical or hilar lymph nodes)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>HSV bronchitis, pneumonitis, or oesophagitis with onset before age 1 month</P>
</TD>
<TD>
<P>Kaposi's sarcoma</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Herpes zoster (e.g. shingles) involving at least 2 distinct episodes or more than one dermatome</P>
</TD>
<TD>
<P>Lymphoma, primary, in brain</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Leiomyosarcoma</P>
</TD>
<TD>
<P>Lymphoma, small, noncleaved cell (Burkitt's), or immunoblastic or large cell lymphoma of B cell or unknown immunologic phenotype</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Lymphoid interstitial pneumonia (LIP) or pulmonary lymphoid hyperplasia complex</P>
</TD>
<TD>
<P>Pneumocystis carinii pneumonia (PCP)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Nephropathy</P>
</TD>
<TD>
<P>Progressive multifocal leukoencephalopathy (PML)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Nocardiosis</P>
</TD>
<TD>
<P>Salmonella (nontyphoid) septicaemia, recurrent</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Fever lasting &gt;1 month</P>
</TD>
<TD>
<P>Toxoplasmosis of the brain with onset at age &gt;1 month</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Toxoplasmosis with onset before age 1 month</P>
</TD>
<TD>
<P>
<I>Mycobacterium tuberculosis</I>, disseminated or extrapulmonary <I>Mycobacterium</I>, other species or unidentified species, disseminated (at site other than or in addition to lungs, skin, or cervical or hilar lymph nodes)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Varicella, disseminated (e.g. complicated chickenpox)</P>
</TD>
<TD>
<P>
<I>Mycobacterium avium</I> complex or <I>Mycobacterium kansasii</I>, disseminated (at site other than or in addition to lungs, skin, cervical or hilar lymph nodes)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2008-11-11 12:49:36 -0800" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-11-11 12:49:36 -0800" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>World Health Organization: Clinical Staging of HIV for Infants and Children</TITLE>
<TABLE COLS="4" ROWS="19">
<TR>
<TH>
<P>Clinical stage 1</P>
</TH>
<TH>
<P>Clinical stage 2</P>
</TH>
<TH>
<P>Clinical stage 3</P>
</TH>
<TH>
<P>Clinical stage 4</P>
</TH>
</TR>
<TR>
<TD>
<P>Asymptomatic</P>
</TD>
<TD>
<P>Unexplained persistent hepatosplenomegaly</P>
</TD>
<TD>
<P>Unexplained malnutrition not adequately responding to standard therapy</P>
</TD>
<TD>
<P>Unexplained severe wasting, stunting or severe malnutrition not responding to standard therapy</P>
</TD>
</TR>
<TR>
<TD>
<P>Persistent generalized lymphadenopathy</P>
</TD>
<TD>
<P>Papular pruritic eruptions</P>
</TD>
<TD>
<P>Unexplained persisitent diarrhoea (14 days or more)</P>
</TD>
<TD>
<P>Pneumocystis pneumonia</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Extensive wart virus infection</P>
</TD>
<TD>
<P>Unexplained persistent fever (above 37.5 Celsius, intermittent or constant, for longer than 1 month)</P>
</TD>
<TD>
<P>Recurrent severe bacterial infections (e.g. empyema, pyomyositis, bone or joint infection, meningitis) excluding pneumonia</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Extensive molluscum contagiosum</P>
</TD>
<TD>
<P>Persistent oral candidiasis (after first 6 weeks of life)</P>
</TD>
<TD>
<P>Chronic herpes simplex infection; orolabial or cutaneous of more than one month's duration, or visceral at any site</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Recurrent oral ulcerations</P>
</TD>
<TD>
<P>Oral hairy leukoplakia</P>
</TD>
<TD>
<P>Extrapulmonary tuberculosis</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Unexplained persistent parotid enlargement</P>
</TD>
<TD>
<P>Acute necrotizing ulcerative gingivitis/periodontitis</P>
</TD>
<TD>
<P>Kaposi sarcoma</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Lineal gingival erythema</P>
</TD>
<TD>
<P>Lymph node tuberculosis</P>
</TD>
<TD>
<P>Oesophageal candidiasis (or candida of trachea, bronchi, or lungs)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Herpes zoster</P>
</TD>
<TD>
<P>Pulmonary tuberculosis</P>
</TD>
<TD>
<P>Central nervous system toxoplasmosis (after neonatal period)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Recurrent or chronic upper respiratory tract infections (otitis media, otorrhoea, sinusitis, tonsillitis)</P>
</TD>
<TD>
<P>Severe recurrent bacterial pneumonia</P>
</TD>
<TD>
<P>HIV encephalopathy</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Fungal nail infections</P>
</TD>
<TD>
<P>Symptomatic lymphoid intersitial pneumonitis</P>
</TD>
<TD>
<P>Cytomegalovirus (CMV) infection; retinitis or CMV infection affecting another organ, with onset at age over 1 month</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Chronic HIV-associated lung disease including bronchiectasis</P>
</TD>
<TD>
<P>Extrapulmonary cryptococcosis (including meningitis)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Unexplained anaemia (&lt;8.0 g/dL), neutropenia (&lt;500/mm<SUP>3</SUP>), or chronic thrombocytopenia (&lt;50 000/mm<SUP>3</SUP>)</P>
</TD>
<TD>
<P>Disseminated endemic mycosis (extrapulmonary histoplasmosis, coccidiomycosis)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Chronic cryptosporidiosis (with diarrhoea)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Chronic isosporiasis</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Disseminated non-tuberculous mycobacterial infection</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Cerebral or B cell non-Hodgkin lymphoma</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Progressive multifocal leukoencephalopathy</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>HIV-associated cardiomyopathy or nephropathy</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" NO="3">
<TITLE>PUBMED search strategy</TITLE>
<TABLE COLS="3" ROWS="7">
<TR>
<TH>
<P>Search</P>
</TH>
<TH>
<P>Search terms</P>
</TH>
<TH>
<P>Results</P>
</TH>
</TR>
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>Search HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tw] OR hiv-1*[tw] OR hiv-2*[tw] OR hiv1[tw] OR hiv2[tw] OR hiv infect*[tw] OR human immunodeficiency virus[tw] OR human immunedeficiency virus[tw] OR human immuno-deficiency virus[tw] OR human immune-deficiency virus[tw] OR ((human immun*) AND (deficiency virus[tw])) OR acquired immunodeficiency syndrome[tw] OR acquired immunedeficiency syndrome[tw] OR acquired immuno-deficiency syndrome[tw] OR acquired immune-deficiency syndrome[tw] OR ((acquired immun*) AND (deficiency syndrome[tw])) OR "sexually transmitted diseases, viral"[MESH:NoExp]</P>
</TD>
<TD>
<P>228146</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>Search randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR ("clinical trial" [tw]) OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR ( placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] OR (comparative study) OR (comparative studies) OR (evaluation studies) OR follow-up studies [mh] OR prospective studies [mh] OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animals [mh] NOT human [mh])</P>
</TD>
<TD>
<P>3697500</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>Search (FERROUS SALT) OR (FERROUS SALT) OR (FERROUS GLUCONATE) OR (FERROUS SULPHATE) OR (FERROUS LACTATE) OR (FERROUS FUMARATE) OR (IRON AMINO ACID CHELATE) OR (FERROUS SULFATE) OR (IRON DEXTRAN) OR (IRON SORBITOL) OR (IRON SUCROSE) OR (SODIUM FERRIC GLUCONATE) OR (IRON-POLYSACCHARIDE) OR (IRON POLYSACCHARIDE) OR FERROUS COMPOUNDS[MH:EXP] OR IRON COMPOUNDS[MH:EXP] OR (IRON-DEXTRAN COMPLEX) OR FERRIC COMPOUNDS[MH:EXP]<BR/>
<BR/>
</P>
</TD>
<TD>
<P>36706</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>Search (IRON SUPPLEMENTATION) OR (IRON DEFICIENCY) OR (IRON AND (DIETARY SUPPLEMENTS[MH])) OR (SUPPLEMENTARY IRON) OR (IRON DEFICIENCY ANEMIA) OR (IRON-DEFICIENCY ANEMIA) OR (IRON DEFICIENCY ANEMIAS) OR (IRON-DEFICIENCY ANEMIAS) OR (IRON DEFICIENCY ANAEMIA) OR (IRON-DEFICIENCY ANAEMIA) OR (IRON DEFICIENCY ANAEMIAS) OR (IRON-DEFICIENCY ANAEMIAS) OR ANEMIA, IRON-DEFICIENCY[MH]</P>
</TD>
<TD>
<P>18407</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>Search #3 OR #4</P>
</TD>
<TD>
<P>52575</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>Search #1 AND #2 AND #5 Limits: Publication Date from 1980 to 2008<BR/>
<BR/>
</P>
</TD>
<TD>
<P>89</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" NO="4">
<TITLE>EMBASE search strategy</TITLE>
<TABLE COLS="3" ROWS="7">
<TR>
<TH>
<P>Search</P>
</TH>
<TH>
<P>Search terms</P>
</TH>
<TH>
<P>Results</P>
</TH>
</TR>
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>iron supplementation' OR (('iron deficiency'/exp OR 'iron deficiency') OR ('iron deficiency'/de OR 'iron deficiency')) OR ((('iron'/exp OR 'iron') OR ('iron'/de OR 'iron')) AND (('dietary supplements'/exp OR 'dietary supplements') OR ('dietary supplements'/de OR 'dietary supplements'))) OR 'supplementary iron' OR (('iron deficiency anemia'/exp OR 'iron deficiency anemia') OR ('iron deficiency anemia'/de OR 'iron deficiency anemia')) OR (('iron-deficiency anemia'/exp OR 'iron-deficiency anemia') OR ('iron-deficiency anemia'/de OR 'iron-deficiency anemia')) OR 'iron deficiency anemias' OR 'iron-deficiency anemias' OR (('iron deficiency anaemia'/exp OR 'iron deficiency anaemia') OR ('iron deficiency anaemia'/de OR 'iron deficiency anaemia')) OR (('iron-deficiency anaemia'/exp OR 'iron-deficiency anaemia') OR ('iron-deficiency anaemia'/de OR 'iron-deficiency anaemia')) OR 'iron deficiency anaemias' OR 'iron-deficiency anaemias' OR (('anemia iron-deficiency'/exp OR 'anemia iron-deficiency') OR ('anemia iron-deficiency'/de OR 'anemia iron-deficiency'))</P>
</TD>
<TD>
<P>22381</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>'ferrous salt' OR (('ferrous gluconate'/exp OR 'ferrous gluconate') OR ('ferrous gluconate'/de OR 'ferrous gluconate')) OR 'ferrous sulphate' OR 'ferrous lactate' OR (('ferrous fumarate'/exp OR 'ferrous fumarate') OR ('ferrous fumarate'/de OR 'ferrous fumarate')) OR 'iron amino acid chelate' OR (('ferrous sulfate'/exp OR 'ferrous sulfate') OR ('ferrous sulfate'/de OR 'ferrous sulfate')) OR (('iron dextran'/exp OR 'iron dextran') OR ('iron dextran'/de OR 'iron dextran')) OR (('iron sorbitol'/exp OR 'iron sorbitol') OR ('iron sorbitol'/de OR 'iron sorbitol')) OR (('iron sucrose'/exp OR 'iron sucrose') OR ('iron sucrose'/de OR 'iron sucrose')) OR (('sodium ferric gluconate'/exp OR 'sodium ferric gluconate') OR ('sodium ferric gluconate'/de OR 'sodium ferric gluconate')) OR 'iron-polysaccharide' OR 'iron polysaccharide' OR (('ferrous compounds'/exp OR 'ferrous compounds') OR ('ferrous compounds'/de OR 'ferrous compounds')) OR (('iron compounds'/exp OR 'iron compounds') OR ('iron compounds'/de OR 'iron compounds')) OR (('iron-dextran complex'/exp OR 'iron-dextran complex') OR ('iron-dextran complex'/de OR 'iron-dextran complex')) OR (('ferric compounds'/exp OR 'ferric compounds') OR ('ferric compounds'/de OR 'ferric compounds'))</P>
</TD>
<TD>
<P>19021</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>('human immunodeficiency virus infection'/exp OR 'human immunodeficiency virus infection') OR (('human immunodeficiency virus'/exp OR 'human immunodeficiency virus')) OR (('b cell lymphoma'/de OR 'b cell lymphoma')) OR (hiv:ti OR hiv:ab) OR ('hiv-1':ti OR 'hiv-1':ab) OR ('hiv-2':ti OR 'hiv-2':ab) OR ('human immunodeficiency virus':ti OR 'human immunodeficiency virus':ab) OR ('human immunedeficiency virus':ti OR 'human immunedeficiency virus':ab) OR ('human immune-deficiency virus':ti OR 'human immune-deficiency virus':ab) OR ('human immuno-deficiency virus':ti OR 'human immuno-deficiency virus':ab) OR ('acquired immunodeficiency syndrome':ti OR 'acquired immunodeficiency syndrome':ab) OR ('acquired immuno-deficiency syndrome':ti OR 'acquired immuno-deficiency syndrome':ab) OR ('acquired immune-deficiency syndrome':ti OR 'acquired immune-deficiency syndrome':ab) OR ('acquired immunedeficiency syndrome':ti OR 'acquired immunedeficiency syndrome':ab)</P>
</TD>
<TD>
<P>287089</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>((random*:ti OR random*:ab) OR (factorial*:ti OR factorial*:ab) OR (cross?over*:ti OR cross?over*:ab OR crossover*:ti OR crossover*:ab) OR (placebo*:ti OR placebo*:ab) OR ((doubl*:ti AND blind*:ti) OR (doubl*:ab AND blind*:ab)) OR ((singl*:ti AND blind*:ti) OR (singl*:ab AND blind*:ab)) OR (assign*:ti OR assign*:ab) OR (allocat*:ti OR allocat*:ab) OR (volunteer*:ti OR volunteer*:ab) OR (('crossover procedure'/de OR 'crossover procedure')) OR (('double-blind procedure'/de OR 'double-blind procedure')) OR (('single-blind procedure'/de OR 'single-blind procedure')) OR (('randomized controlled trial'/de OR 'randomized controlled trial')))</P>
</TD>
<TD>
<P>784293</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>#1 OR #2</P>
</TD>
<TD>
<P>38743</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>#3 AND #4 AND #5 AND [1980-2008]/py</P>
</TD>
<TD>
<P>38</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" NO="5">
<TITLE>AIDSearch Strategy</TITLE>
<TABLE COLS="3" ROWS="8">
<TR>
<TH>
<P>Search</P>
</TH>
<TH>
<P>Matches</P>
</TH>
<TH>
<P>Search strategy</P>
</TH>
</TR>
<TR>
<TD>
<P>#1 <BR/>
</P>
</TD>
<TD>
<P>269,827</P>
</TD>
<TD>
<P>(HIV INFECTIONS) OR HIV OR HIV OR HIV-1* OR HIV-2* OR HIV1 OR HIV2 OR (HIV INFECT*) OR (HUMAN IMMUNODEFICIENCY VIRUS) OR (HUMAN IMMUNEDEFICIENCY VIRUS) OR (HUMAN IMMUNO-DEFICIENCY VIRUS) OR (HUMAN IMMUNE-DEFICIENCY VIRUS) OR ((HUMAN IMMUN*) AND (DEFICIENCY VIRUS)) OR (ACQUIRED IMMUNODEFICIENCY SYNDROME) OR (ACQUIRED IMMUNEDEFICIENCY SYNDROME) OR (ACQUIRED IMMUNO-DEFICIENCY SYNDROME) OR (ACQUIRED IMMUNE-DEFICIENCY SYNDROME) OR ((ACQUIRED IMMUN*) AND (DEFICIENCY SYNDROME)) OR (SEXUALLY TRANSMITTED DISEASES, VIRAL)</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>153,716</P>
</TD>
<TD>
<P>((RANDOMIZED CONTROLLED TRIAL) OR (CONTROLLED CLINICAL TRIAL) OR (RANDOMIZED CONTROLLED TRIALS) OR (RANDOM ALLOCATION) OR (DOUBLE-BLIND METHOD) OR (SINGLE-BLIND METHOD) OR (CLINICAL TRIAL) OR (CLINICAL TRIALS) OR ("CLINICAL TRIAL") OR ((SINGL* OR DOUBL* OR TREBL* OR TRIPL* AND (MASK* OR BLIND* )) OR PLACEBOS OR PLACEBO* OR RANDOM* OR (COMPARATIVE STUDY) OR (EVALUATION STUDIES) OR (FOLLOW-UP STUDIES) OR (PROSPECTIVE STUDIES) OR CONTROL* OR PROSPECTIV* OR VOLUNTEER*)) NOT (ANIMALS NOT HUMAN )</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>109,587</P>
</TD>
<TD>
<P>#1 AND #2</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>(FERROUS SALT) OR (FERROUS GLUCONATE) OR (FERROUS SULPHATE) OR (FERROUS LACTATE) OR (FERROUS FUMARATE) OR (IRON AMINO ACID CHELATE) OR (FERROUS SULFATE) OR (IRON DEXTRAN) OR (IRON SORBITOL) OR (IRON SUCROSE) OR (SODIUM FERRIC GLUCONATE) OR (IRON-POLYSACCHARIDE) OR (IRON POLYSACCHARIDE) OR (FERROUS COMPOUNDS) OR (IRON COMPOUNDS) OR (IRON-DEXTRAN COMPLEX) OR (FERRIC COMPOUNDS)</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>148</P>
</TD>
<TD>
<P>(IRON SUPPLEMENTATION) OR (IRON DEFICIENCY) OR (IRON AND (DIETARY SUPPLEMENTS)) OR (SUPPLEMENTARY IRON) OR (IRON DEFICIENCY ANEMIA) OR (IRON-DEFICIENCY ANEMIA) OR (IRON DEFICIENCY ANEMIAS) OR (IRON-DEFICIENCY ANEMIAS) OR (IRON DEFICIENCY ANAEMIA) OR (IRON-DEFICIENCY ANAEMIA) OR (IRON DEFICIENCY ANAEMIAS) OR (IRON-DEFICIENCY ANAEMIAS) OR (ANEMIA, IRON-DEFICIENCY)</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>243</P>
</TD>
<TD>
<P>#4 OR #5</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>#3 AND #6</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" NO="6">
<TITLE>GATEWAY strategy</TITLE>
<TABLE COLS="3" ROWS="6">
<TR>
<TH>
<P>Search</P>
</TH>
<TH>
<P>Search terms</P>
</TH>
<TH>
<P>Results</P>
</TH>
</TR>
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>Search: ((HIV INFECTIONS) OR HIV OR HIV OR HIV-1* OR HIV-2* OR HIV1 OR HIV2 OR (HIV INFECT*) OR (HUMAN IMMUNODEFICIENCY VIRUS) OR (HUMAN IMMUNEDEFICIENCY VIRUS) OR (HUMAN IMMUNO-DEFICIENCY VIRUS) OR (HUMAN IMMUNE-DEFICIENCY VIRUS) OR ((HUMAN IMMUN*) AND (DEFICIENCY VIRUS)) OR (ACQUIRED IMMUNODEFICIENCY SYNDROME)) OR ((ACQUIRED IMMUNEDEFICIENCY SYNDROME) OR (ACQUIRED IMMUNO-DEFICIENCY SYNDROME) OR (ACQUIRED IMMUNE-DEFICIENCY SYNDROME) OR ((ACQUIRED IMMUN*) AND (DEFICIENCY SYNDROME)) OR (SEXUALLY TRANSMITTED DISEASES, VIRAL))</P>
</TD>
<TD>
<P>330943</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>Search: ((RANDOMIZED CONTROLLED TRIAL) OR (CONTROLLED CLINICAL TRIAL) OR (RANDOMIZED CONTROLLED TRIALS) OR (RANDOM ALLOCATION) OR (DOUBLE-BLIND METHOD) OR (SINGLE-BLIND METHOD) OR (CLINICAL TRIAL) OR (CLINICAL TRIALS) OR (CLINICAL TRIAL) OR ((SINGL* OR DOUBL* OR TREBL* OR TRIPL*) AND (MASK* OR BLIND* ))) OR (PLACEBOS OR PLACEBO* OR RANDOM* OR (COMPARATIVE STUDY) OR (EVALUATION STUDIES) OR (FOLLOW-UP STUDIES) OR (PROSPECTIVE STUDIES) OR CONTROL* OR PROSPECTIV* OR VOLUNTEER*)</P>
</TD>
<TD>
<P>99536</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>Search: ((IRON SUPPLEMENTATION) OR (IRON DEFICIENCY) OR (IRON AND (DIETARY SUPPLEMENTS[MH])) OR (SUPPLEMENTARY IRON) OR (IRON DEFICIENCY ANEMIA) OR (IRON-DEFICIENCY ANEMIA) OR (IRON DEFICIENCY ANEMIAS) OR (IRON-DEFICIENCY ANEMIAS) OR (IRON DEFICIENCY ANAEMIA) OR (IRON-DEFICIENCY ANAEMIA) OR (IRON DEFICIENCY ANAEMIAS) OR (IRON-DEFICIENCY ANAEMIAS) OR ANEMIA, IRON-DEFICIENCY[MH]) OR ((FERROUS SALT) OR (FERROUS GLUCONATE) OR (FERROUS SULPHATE) OR (FERROUS LACTATE) OR (FERROUS FUMARATE) OR (IRON AMINO ACID CHELATE) OR (FERROUS SULFATE) OR (IRON DEXTRAN) OR (IRON SORBITOL) OR (IRON SUCROSE) OR (SODIUM FERRIC GLUCONATE) OR (IRON-POLYSACCHARIDE) OR (IRON POLYSACCHARIDE) OR FERROUS COMPOUNDS[MH] OR IRON COMPOUNDS[MH] OR (IRON-DEXTRAN COMPLEX) OR FERRIC COMPOUNDS[MH])</P>
</TD>
<TD>
<P>55459</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>Search: (((HIV INFECTIONS) OR HIV OR HIV OR HIV-1* OR HIV-2* OR HIV1 OR HIV2 OR (HIV INFECT*) OR (HUMAN IMMUNODEFICIENCY VIRUS) OR (HUMAN IMMUNEDEFICIENCY VIRUS) OR (HUMAN IMMUNO-DEFICIENCY VIRUS) OR (HUMAN IMMUNE-DEFICIENCY VIRUS) OR ((HUMAN IMMUN*) AND (DEFICIENCY VIRUS)) OR (ACQUIRED IMMUNODEFICIENCY SYNDROME)) OR ((ACQUIRED IMMUNEDEFICIENCY SYNDROME) OR (ACQUIRED IMMUNO-DEFICIENCY SYNDROME) OR (ACQUIRED IMMUNE-DEFICIENCY SYNDROME) OR ((ACQUIRED IMMUN*) AND (DEFICIENCY SYNDROME)) OR (SEXUALLY TRANSMITTED DISEASES, VIRAL))) AND (((RANDOMIZED CONTROLLED TRIAL) OR (CONTROLLED CLINICAL TRIAL) OR (RANDOMIZED CONTROLLED TRIALS) OR (RANDOM ALLOCATION) OR (DOUBLE-BLIND METHOD) OR (SINGLE-BLIND METHOD) OR (CLINICAL TRIAL) OR (CLINICAL TRIALS) OR (CLINICAL TRIAL) OR ((SINGL* OR DOUBL* OR TREBL* OR TRIPL*) AND (MASK* OR BLIND* ))) OR (PLACEBOS OR PLACEBO* OR RANDOM* OR (COMPARATIVE STUDY) OR (EVALUATION STUDIES) OR (FOLLOW-UP STUDIES) OR (PROSPECTIVE STUDIES) OR CONTROL* OR PROSPECTIV* OR VOLUNTEER*)) AND (((IRON SUPPLEMENTATION) OR (IRON DEFICIENCY) OR (IRON AND (DIETARY SUPPLEMENTS[MH])) OR (SUPPLEMENTARY IRON) OR (IRON DEFICIENCY ANEMIA) OR (IRON-DEFICIENCY ANEMIA) OR (IRON DEFICIENCY ANEMIAS) OR (IRON-DEFICIENCY ANEMIAS) OR (IRON DEFICIENCY ANAEMIA) OR (IRON-DEFICIENCY ANAEMIA) OR (IRON DEFICIENCY ANAEMIAS) OR (IRON-DEFICIENCY ANAEMIAS) OR ANEMIA, IRON-DEFICIENCY[MH]) OR ((FERROUS SALT) OR (FERROUS GLUCONATE) OR (FERROUS SULPHATE) OR (FERROUS LACTATE) OR (FERROUS FUMARATE) OR (IRON AMINO ACID CHELATE) OR (FERROUS SULFATE) OR (IRON DEXTRAN) OR (IRON SORBITOL) OR (IRON SUCROSE) OR (SODIUM FERRIC GLUCONATE) OR (IRON-POLYSACCHARIDE) OR (IRON POLYSACCHARIDE) OR FERROUS COMPOUNDS[MH] OR IRON COMPOUNDS[MH] OR (IRON-DEXTRAN COMPLEX) OR FERRIC COMPOUNDS[MH])) Limit: 1980:2007</P>
</TD>
<TD>
<P>71</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>13 meeting abstracts found</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" NO="7">
<TITLE>Cochrane Clinical Trials Register</TITLE>
<TABLE COLS="3" ROWS="6">
<TR>
<TH>
<P>Search</P>
</TH>
<TH>
<P>Search terms</P>
</TH>
<TH>
<P>Results</P>
</TH>
</TR>
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>("HIV INFECTIONS" in All Text or HIV in All Text or HIV in All Text or "HIV-1*" in All Text or "HIV-2*" in All Text or HIV1 in All Text or HIV2 in All Text or "HIV INFECT*" in All Text or "HUMAN IMMUNODEFICIENCY VIRUS" in All Text or "HUMAN IMMUNEDEFICIENCY VIRUS" in All Text or "HUMAN IMMUNO-DEFICIENCY VIRUS" in All Text or "HUMAN IMMUNE-DEFICIENCY VIRUS" in All Text or ("HUMAN IMMUN*" in All Text and "DEFICIENCY VIRUS" in All Text) or "ACQUIRED IMMUNODEFICIENCY SYNDROME" in All Text or "ACQUIRED IMMUNEDEFICIENCY SYNDROME" in All Text or "ACQUIRED IMMUNO-DEFICIENCY SYNDROME" in All Text or "ACQUIRED IMMUNE-DEFICIENCY SYNDROME" in All Text or ("ACQUIRED IMMUN*" in All Text and "DEFICIENCY SYNDROME" in All Text) or "SEXUALLY TRANSMITTED DISEASES, VIRAL" in All Text)</P>
</TD>
<TD>
<P>7230</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>("IRON SUPPLEMENTATION" in All Text or "IRON DEFICIENCY" in All Text or "IRON AND (DIETARY SUPPLEMENTS)" in All Text or "SUPPLEMENTARY IRON" in All Text or "IRON DEFICIENCY ANEMIA" in All Text or "IRON-DEFICIENCY ANEMIA" in All Text or "IRON DEFICIENCY ANEMIAS" in All Text or "IRON-DEFICIENCY ANEMIAS" in All Text or "IRON DEFICIENCY ANAEMIA" in All Text or "IRON-DEFICIENCY ANAEMIA" in All Text or "IRON DEFICIENCY ANAEMIAS" in All Text or "IRON-DEFICIENCY ANAEMIAS" in All Text or "ANEMIA, IRON-DEFICIENCY" in All Text)</P>
</TD>
<TD>
<P>1155</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>("FERROUS SALT" in All Text or "FERROUS SALT" in All Text or "FERROUS GLUCONATE" in All Text or "FERROUS SULPHATE" in All Text or "FERROUS LACTATE" in All Text or "FERROUS FUMARATE" in All Text or "IRON AMINO ACID CHELATE" in All Text or "FERROUS SULFATE" in All Text or "IRON DEXTRAN" in All Text or "IRON SORBITOL" in All Text or "IRON SUCROSE" in All Text or "SODIUM FERRIC GLUCONATE" in All Text or "IRON-POLYSACCHARIDE" in All Text or "IRON POLYSACCHARIDE" in All Text or "FERROUS COMPOUNDS" in All Text or "IRON COMPOUNDS" in All Text or "IRON-DEXTRAN COMPLEX" in All Text or "FERRIC COMPOUNDS" in All Text)</P>
</TD>
<TD>
<P>730</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>(#2 or #3)</P>
</TD>
<TD>
<P>1497</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>(#1 and #4) from 1980 to 2007</P>
</TD>
<TD>
<P>30</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>